Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress

Kuo-Kai Chin, Andriy Derkach, Leora Boussi, Gabrielle Melamed, Giulia Petrone, Kelly Bolton, Maher Abdul Hay, Jessica Altman, Andrew Intlekofer, Eytan Stein

Blood (2025) 146 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2025-1690

Published: 2025

Journal Articles

A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias

Kuo-Kai Chin, Sheng Cai, Andriy Derkach, Gabrielle Melamed, Natalie Smith, Neerav Shukla, Joshua Zeidner, Ibrahim Aldoss, Ghayas Issa, Eytan Stein

Blood (2025) 146 (Supplement 1): 1657.

https://doi.org/10.1182/blood-2025-1657

Published: 2025

Journal Articles

A Phase 1b Multi-Center Study of the FLT3 Inhibitor Gilteritinib in Combination with the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring FLT3/IDH1 or FLT3/IDH2 Mutations

Eytan M. Stein, Andriy Derkach, Gabrielle Melamed, Alana Block, Janet Kim, Gergana Georgieva, Vanessa Thompson, Ross L Levine, Andrew M. Intlekofer, Omar Abdel-Wahab, Martin S. Tallman

Blood (2023) 142 (Supplement 1): 5945.

https://doi.org/10.1182/blood-2023-190801

Published: 2023